ArticleInternational journal of inflammation2012
Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.
Article in International journal of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 65 citations in OpenAlex.
- Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.Annals of the rheumatic diseases · 2018Trial
- Advancing Precision Medicine in Adult-Onset Still's Disease: Insights into Biomarkers, Therapies, and COVID-19 Impacts.Mediterranean journal of rheumatology · 2025Review
- Autoimmune rheumatic transitional care model development.BMC rheumatology · 2024Article
- Review
- The Great Still-Usion: Unmasking Adult-Onset Still's Disease Masquerading As Upper Respiratory Tract Infection.Cureus · 2023Article
- Adult-Onset Still's Disease-A Complex Disease, a Challenging Treatment.International journal of molecular sciences · 2022Review
- Adult-onset Still's disease with concurrent acute necrotizing encephalopathy: a case report.BMC neurology · 2022Article
- Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.Frontiers in immunology · 2022Review
- Article
- Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still's Disease and Active Articular Manifestation Responding to Canakinumab.Journal of clinical medicine · 2021Article
- The Association of ATG16L1 Variations with Clinical Phenotypes of Adult-Onset Still's Disease.Genes · 2021Article
- CARD8 SNP rs11672725 Identified as a Potential Genetic Variant for Adult-Onset Still's Disease.Life (Basel, Switzerland) · 2021Article
- An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.Journal of immunology research · 2021Review
- Adult-onset Still's disease and the role of dermatological manifestations: A case report and literature review.Experimental and therapeutic medicine · 2021Article
- Elevated plasma galectin-3 levels and their correlation with disease activity in adult-onset Still's disease.Clinical rheumatology · 2020Article
- Elevated Expression of C-Type Lectin Domain Family 5-Member A (CLEC5A) and Its Relation to Inflammatory Parameters and Disease Course in Adult-Onset Still's Disease.Journal of immunology research · 2020Article
- Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: A STROBE-compliant article.Medicine · 2019Observational
- Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy.Arthritis research & therapy · 2019Article
- Adult-onset Still's Disease in a Female Patient with Schizophrenia: A Case Report and Literature Review.Cureus · 2018Article
- A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.Rheumatology and therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder affecting primarily young individuals. The diagnosis is primarily clinical and necessitates the exclusion of a wide range of mimicking disorders. Given the lack of solid data in regard to the underlying pathogenetic mechanisms, treatment of AOSD has been for years largely empirical. Recent advances have revealed a pivotal role of several proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-18 (IL-18) in disease pathogenesis, giving rise to the development of new targeted therapies aiming at optimal disease control.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.